AURX 10-Q: SEC filing
Nuo Therapeutics
Filed with the SEC on · accession 0001437749-26-036956
AURX filed a 10-Q (quarterly report) with the SEC on Nov 13, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.
Summary of the filing
Nuo Therapeutics filed its Q3 2026 10-Q, reporting continued net losses and a going concern uncertainty, alongside a subsequent October 2026 amendment to its loan agreement with lenders that includes related-party participation and the issuance of contingent warrants.
Key details
✦ Ask GOAX AI about this filing — what it means for AURX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AURX?
Click hereFrequently asked questions
What did AURX file with the SEC on Nov 13, 2026?
AURX filed a 10-Q (SEC filing). Nuo Therapeutics filed its Q3 2026 10-Q, reporting continued net losses and a going concern uncertainty, alongside a subsequent October 2026 amendment to its loan agreement with lenders that includes related-party participation and the issuance of contingent warrants.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other AURX SEC filings
Get alerts when AURX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days